Vis børsmeldingen
INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR HONG KONG
OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION
WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER TO BUY, SELL
OR SUBSCRIBE FOR ANY SECURITIES DESCRIBED HEREIN.
Correction: The total number of New Shares to be issued was incorrect. Please
see updated version below.
Reference is made to the stock exchange notice from Aqua Bio Technology ASA ("
ABT" or the “Company”) published on 17 October 2024 regarding a contemplated
conditional private placement of 19 million new shares towards the shareholders
of Jetcarrier AS and minimum 18.33 million and maximum 22 million new shares
(together, the “New Shares”) towards certain new investors and certain existing
shareholders, at a fixed subscription price of NOK 3 per New Share (the “Private
Placement”).
Reference is also made to the stock exchange announcement by the Company on 17
October 2024, regarding the entry into of a share purchase agreement for the
purchase of all outstanding shares in Jetcarrier AS, between the Company (as
purchaser) and the shareholders of Jetcarrier AS (as sellers) (the "Acquisition
").
The Company is pleased to announce that it has raised approximately NOK 115.09
million in gross proceeds through the Private Placement, where the Company will
issue a total of 38,363,470 New Shares, each at the subscription price of NOK 3
per New Share.
The net proceeds from the Private Placement will be used to repay outstanding
debt and for general corporate purposes.
In connection with the Private Placement, the shareholders of Jetcarrier AS and
RH Investments AS (an investment company closely associated with Roger Hofseth)
have committed to, if the Company decides to carry out a share capital increase
in 2025, participate in such share issue with approximately NOK 16 to 24 million
in total, with the intention to maintain their shareholdings in the Company.
The subscription amounts for the New Shares will be partly settled by conversion
of previously incurred debt (in total approximately NOK 89.25 million, including
NOK 57 million which will be owed to the shareholders of Jetcarrier AS upon
completion of this acquisition) and partly by advance cash payments (in total
approximately NOK 25.84 million).
The issuance of the New Shares, and thus the completion of the Private
Placement, is among other things, subject to all necessary corporate resolutions
for consummating the Private Placement having been validly passed, including
approval of the pertaining share capital increase by an extraordinary general
meeting of the Company (the “EGM”), to be held on or about 12 November 2024. A
notice for the EGM will be distributed in due course. Completion of the Private
Placement is further subject to (i) completion of the Acquisition having
occurred, (ii) valid subscription of the New Shares and the allocated New Shares
having been fully paid, and (iii) registration of the share capital increase
pertaining to the Private Placement with the Norwegian Register of Business
Enterprises.
The New Shares will be delivered to the investors in the Private Placement as
soon as practically possible after the registration of the share capital
increase pertaining to the Private Placement, expected on or about 14 November
2024, initially on a separate ISIN as the listing of the New Shares requires the
preparation and publication of a prospectus approved by the Norwegian Financial
Supervisory Authority.
The following primary insiders or close associates of primary insiders have been
conditionally allocated New Shares:
- Initia AB, a company closely associated with director Jan Pettersson, was
allocated 83,333 New Shares, for a total subscription amount of NOK 250,000;
- Swelandia International AB, a company closely associated with director Jan
Pettersson, was allocated 83,333 New Shares, for a total subscription amount
of NOK 250,000;
- Ødegård Prosjekt AS, a company closely associated with Chairman Jon Olav
Ødegård, was allocated 33,333 New Shares, for a total subscription amount of
NOK 100,000;
- Varming Holding AS, a company closely associated with CFO Jan Varming, was
allocated 1,000,000 New Shares, for a total subscription amount of NOK
3,000,000…
Formal primary insider notifications will be provided once the Private Placement
is unconditional.
Equal treatment
The Private Placement implies a deviation from the pre-emptive rights of the
Company’s existing shareholders. When resolving to conditionally complete the
Private Placement, the Board has considered the Private Placement in light of
the equal treatment obligations under the Norwegian Public Limited Companies
Act, the Norwegian Securities Trading Act, Oslo Børs’ Circular no. 2/2014 and
the rules on equal treatment under Oslo Rule Book II for companies listed on the
Oslo Stock Exchange, and is of the opinion that the contemplated Private
Placement is in compliance with these requirements.
The Board, together with the Company’s management, has considered various
transaction alternatives to secure new financing. Based on an overall
assessment, taking into account inter alia the need for funding, execution risk
and possible alternatives, the Board has on the basis of careful considerations
decided that the Private Placement is the alternative that best protects the
Company’s and the shareholders’ joint interests. Thus, the deviation of the
preferential rights inherent in a share capital increase through issuance of New
Shares is considered necessary. Further, the Board has considered that the
Subsequent Offering (as defined below) will (if implemented) mitigate some of
the dilutive effect on the shareholdings who did not participate in the Private
Placement.
Subsequent Offering
The Board has resolved an intention to carry out a subsequent offering (the "
Subsequent Offering") of up to 2,000,000 new shares (the “Offer Shares”) in the
Company, to raise gross proceeds of up to NOK 6,000,000, where each Offer Share
may be subscribed at the same subscription price as in the Private Placement,
i.e. NOK 3 per new share.
If implemented, the Subsequent Offering will be directed towards existing
shareholders in the Company as of 17 October 2024 (as registered in the VPS on
21 October 2024) who; (i) were not allocated New Shares in the Private
Placement, and (ii) are not resident in jurisdictions where such offering would
be unlawful, or would require any prospectus filing, registration or similar
action.
The issuance of Offer Shares in the Subsequent Offering will be subject to
approval of the pertaining share capital increase by the EGM to be held on or
about 12 November 2024. The Subsequent Offering is expected to be carried out
during the notice period for the EGM, with a one-week subscription period,
expected to expire at least three days prior to the date of the EGM.
The Subsequent Offering is among other things subject to the completion of the
Private Placement, and the Company reserves the right in its sole discretion to
not conduct or cancel the Subsequent Offering. More details about the Subsequent
Offering will follow.
The Offer Shares will initially be delivered on a separate ISIN as the listing
of the Offer Shares requires the preparation and publication of a prospectus
approved by the Norwegian Financial Supervisory Authority.
For further information, please contact Jan Varming, CFO, telephone +47 90 83 90
76.
Aqua Bio Technology (ABT) is developing and commercializing sustainable
biotechnology for use in skincare products. ABT’s cosmetics ingredients are
highly effective, and they provide the cosmetics industry with natural
alternatives to traditional ingredients. ABT is also marketing and distributing
natural skincare products developed by partners towards consumers and
professional users. ABT’s focus on commercialization and development of natural
ingredients and natural skincare products has been, and will continue to be, an
important part of the Company’s strategy going forward. ABT is listed on the
Euronext Expand market of the Oslo Stock Exchange.
This information is considered to be inside information pursuant to the EU
Market Abuse Regulation (MAR) and is subject to the disclosure requirements
pursuant to MAR article 17 and section 5-12 of the Norwegian Securities Trading
Act.
The stock exchange announcement was published by CFO Jan Varming on the time and
date provided.
IMPORTANT INFORMATION
This announcement is not an offer to sell or a solicitation of offers to
purchase or subscribe for shares. Copies of this announcement may not be sent to
jurisdictions, or distributed in or sent from jurisdictions, in which this is
barred or prohibited by law. The information contained herein shall not
constitute an offer to sell or the solicitation of an offer to buy, in any
jurisdiction in which such offer or solicitation would be unlawful absent
registration, or an exemption from registration or qualification under the
securities laws of any jurisdiction.
This document is not for publication or distribution in, directly or indirectly,
Australia, Canada, Japan, Hong Kong or the United States or any other
jurisdiction in which such release, publication or distribution would be
unlawful, and it does not constitute an offer or invitation to subscribe for or
purchase any securities in such countries or in any other jurisdiction. In
particular, the document and the information contained herein should not be
distributed or otherwise transmitted into the United States or to publications
with a general circulation in the United States of America.
This announcement is not an offer for sale of securities in the United States.
Securities may not be offered or sold in the United States absent registration
with the United States Securities and Exchange Commission or an exemption from
registration under the U.S. Securities Act of 1933, as amended (the “Securities
Act”). The Company does not intend to register any part of the offering in the
United States or to conduct a public offering in the United States of the shares
to which this document relates.
This announcement is for information purposes only and is not to be relied upon
in substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities of the Company.
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect
current expectations and assumptions as to future events and circumstances that
may not prove accurate. A number of material factors could cause actual results
and developments to differ materially from those expressed or implied by these
forward-looking statements.
The Company expressly disclaims any obligation or undertaking to update, review
or revise any statement contained in this announcement whether as a result of
new information, future developments or otherwise.
DISCLOSURE REGULATION
This information is subject of the disclosure requirements pursuant to section
of 5-12 of the Norwegian Securities Trading Act.
CONTACTS
- Jan Aas Varming, CFO, Aqua Bio Technology ASA, +47 908 39 076,
jan@aquabiotech.no
ABOUT AQUA BIO TECHNOLOGY ASA
Aqua Bio Technology (ABT) is developing and commercializing sustainable
biotechnology for use in skin care products. ABT’s cosmetics ingredients are
highly effective and they provide the cosmetics industry with natural
alternatives to traditional ingredients. ABT is also marketing and distributing
natural skin care products developed by partners towards consumers and
professional users. Aqua Bio Technology is listed on Euronext Expand.
ATTACHMENTS
Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17847556/18286254/5131/Download%20announce
ment%20as%20PDF.pdf
ORIGINAL RELEASE
Aqua Bio Technology ASA - Private Placement successfully placed -
Aqua Bio Technology ASA – Private Placement successfully placed | Aqua Bio Technology ASA
Kilde
